62388 The evaluation of adequate clinical response to systemic therapy as measured by the Merit-based Incentive Payment System (MIPS) #410 psoriasis quality measure in patients treated with deucravacitinib: a RePhlect 6-month follow-up study - 01/09/25
Doi : 10.1016/j.jaad.2025.05.1247
Le texte complet de cet article est disponible en PDF.
| Commercial Disclosure: This study was a collaborative effort between CorEvitas and Bristol Myers Squibb; financial support for the study was provided by Bristol Myers Squibb. The registry is sponsored by CorEvitas, LLC. |
© 2025
Publié par Elsevier Masson SAS.
Vol 93 - N° 3S
P. AB316 - septembre 2025 Retour au numéro
Article précédent
- 64420 The efficacy of spesolimab in patients with generalized pustular psoriasis (GPP) who received biologics prior to randomization in EFFISAYIL® 2
- Joseph F. Merola, Mark G. Lebwohl, Jeff Crowley, Jason E. Hawkes, Ricardo Romiti, Richard B. Warren, Akimichi Morita, Ming Tang, Patrick Hofmann, Christian Thoma, Bruce Strober
- 62820 The Evolution of Sunscreen from Ancient Egypt to Modern Day: A historical perspective
- Michelle Anthony, Christopher Farkouh, Amritpal Kooner, Parsa Abdi, Zachary Shaw, Conor Dolehide
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?